['esophageal cancer', 's-1', 'radiotherapy']
['s-1']

        Inclusion Criteria:

          1. Cytologically or histologically confirmed esophageal carcinoma;

          2. ECOG performance status: 0-1;

          3. No treatments prior to enrollment;

          4. At least one measurable lesion on CT, MRI or esophageal barium exam;

          5. Normal functions of heart, lung, liver, kidney and bone marrow;

          6. Blood exams qualified for chemotherapy, which included hemoglobulin ≥9 g/dl,
             neutrophil ≥1.5×109/L and platelet (PLT) ≥100×109/L, creatinine ≤1.5 UNL;

          7. Informed consent signed.

        Exclusion Criteria:

          1. Prior treatments of chemotherapy or irradiation;

          2. Poor bone marrow, liver and kidney functions, which would make chemotherapy
             intolerable;

          3. Contraindication for irradiation: complete obstruction of esophagus, deep esophageal
             ulcer, fistula to mediastinum, or haematemesis;

          4. Participating in other clinical trials;

          5. Clinically significant and uncontrolled major medical conditions including but not
             limited to: active uncontrolled infection, symptomatic congestive heart failure,
             Unstable angina pectoris or cardiac arrhythmia, psychiatric illness/ social situation
             that would limit compliance with study requirements; any medical condition, which in
             the opinion of the study investigator places the subject at an unacceptably high risk
             for toxicities;

          6. The subject has had another active malignancy within the past five years except for
             cervical cancer in site, in situ carcinoma of the bladder or non-melanoma carcinoma of
             the skin.
      